The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification ; volume:24 ; number:1 ; day:30 ; month:3 ; year:2024 ; pages:1-11 ; date:12.2024
Cancer cell international ; 24, Heft 1 (30.3.2024), 1-11, 12.2024
- Urheber
-
Weng, Lijuan
Zhou, Jianliang
Guo, Shenchao
Xu, Nong
Ma, Ruishuang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03261-0
- URN
-
urn:nbn:de:101:1-2406171042254.167837430763
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Weng, Lijuan
- Zhou, Jianliang
- Guo, Shenchao
- Xu, Nong
- Ma, Ruishuang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)